On the contrary, the another study showed that elevated expression of TAK1 correlates with reduced disease free survival in patients diagnosed with primary melanoma or colon cancer, indicating that high expression of TAK1 presents a risk factor for disease progression.[9, 10] We speculate that this discrepancy in results may be due to the different kinds of cancers studied (esophageal squamous cancer vs melanoma). Here, MAP3K7 is linked to malignant colon neoplasm.